Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Tunlametinib - Kechow Pharma

Next Previous
Drug Profile

Tunlametinib - Kechow Pharma

Alternative Names: HL-085

Latest Information Update: 03 Jun 2025

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Tianjin Binjiang Pharma
  • Developer Kechow Pharma; Tianjin Binjiang Pharma
  • Class Amides; Aniline compounds; Antineoplastics; Benzothiazoles; Fluorobenzenes; Iodobenzenes; Small molecules
  • Mechanism of Action MAP kinase kinase 1 inhibitors; MAP kinase kinase 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Registered Malignant melanoma
  • Phase III Colorectal cancer
  • Phase II Neurofibromatosis 1; Plexiform neurofibroma; Solid tumours
  • Clinical Phase Unknown Non-small cell lung cancer

Most Recent Events

  • 19 May 2025 Tongji Hospital plans a clinical trial for Colorectal Cancer (Late-stage disease, Combination-therapy, Second-line therapy or greater) (NCT06985316)
  • 31 May 2024 Efficacy and adverse events data from a phase II trial in Malignant melanoma presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 21 Mar 2024 Clinical trials in Colorectal cancer (Combination therapy) in China (PO), before March 2023 (Kechow Pharma pipeline, March 2024)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top